{"abstract": "AbbVie announced that it has agreed to buy Pharmacyclics, a maker of a cancer drug that some analysts predict will eventually become one of the best-selling treatments.", "web_url": "https://www.nytimes.com/2015/03/05/business/dealbook/abbvie-to-pay-21-billion-for-pharmacyclics-maker-of-a-best-selling-cancer-treatment.html", "snippet": "AbbVie announced that it has agreed to buy Pharmacyclics, a maker of a cancer drug that some analysts predict will eventually become one of the best-selling treatments.", "lead_paragraph": "AbbVie announced late Wednesday that it had agreed to buy Pharmacyclics, maker of a cancer drug that some analysts predict will eventually become one of the best-selling treatments for the disease, for about $21 billion.", "print_section": "B", "print_page": "2", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "AbbVie to Pay $21 Billion for Pharmacyclics, Maker of a Promising Cancer Drug", "kicker": null, "content_kicker": null, "print_headline": "AbbVie to Pay $21 Billion for Pharmacyclics, Maker of a Best-Selling Cancer Treatment", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pharmacyclics, Incorporated", "rank": 1, "major": "N"}, {"name": "persons", "value": "de la Merced, Michael J", "rank": 2, "major": "N"}, {"name": "persons", "value": "Pollack, Andrew", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AbbVie Inc", "rank": 4, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 5, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 6, "major": "N"}, {"name": "subject", "value": "Cancer", "rank": 7, "major": "N"}, {"name": "organizations", "value": "Johnson & Johnson", "rank": 8, "major": "N"}], "pub_date": "2015-03-04T23:02:42+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Michael J. de la Merced and Andrew Pollack", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/d9a1bd24-6821-5647-b2c4-070df97be473", "word_count": 725, "uri": "nyt://article/d9a1bd24-6821-5647-b2c4-070df97be473"}